Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market Cannara Biotech reports record FY2024 revenue of $82.2M (+43%), strong Q4 growth, 3.2% national market share, and plans for expanded production.

OxySure (OXYS) Improves Bottom Line as It Ramps Up Revenues FRISCO, Texas, Aug. 21, 2012 (GLOBE NEWSWIRE) -- OxySure Systems Inc. (OTCBB:OXYS), a medical technology company focused on the design, manufacture and distribution of specialty medical and...